KEYNOTE-B59, NCT04977453: GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 430 | US, RoW | GI-101, Pembrolizumab (KEYTRUDA®), KEYTRUDA®, Lenvatinib, Lenvima®, Local Radiotherapy, GI-101A | GI Innovation, Inc., Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Urinary Bladder Cancer, Melanoma, Sarcoma, Microsatellite Stable Colorectal Carcinoma, Merkel Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Cervical Cancer, Vaginal Cancer, Vulvar Cancer | 10/25 | 10/26 | | |
